primary studies - published RCT

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.

Code: PM32969708 **Year:** 2021 **Date:** 2021 **Author:** Griese M

http://dx.doi.org/10.1164/rccm.202008-3176LE

See also

Am J Respir Crit Care Med. 2021 Feb 1;203(3):381-385. doi: 10.1164/rccm.202008-3176LE.

Keywords

Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; elexacaftor; Trikafta; kaftrio;